Home › Research › Drug development
Risk Factors in Coronary Heart Disease
William Bernard Kannel, Thomas R. Dawber, GARY D. FRIEDMAN, WILLIAM E. GLENNON, PATRICIA M. MCNAMARA. Annals of Internal Medicine, 1964-11-01
Topic: Air pollution and environmental exposures
The factors associated with excess risk that have been identified are: serum cholesterol level, blood pressure, cigarette smoking, vital capacity,...References1. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery DiseaseEfficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trialGenetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and “Missing” HeritabilityGesättigte Fettsäuren und kardiovaskuläres RisikoThe burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Is a High HDL-Cholesterol Level Always Beneficial?Milk fat: opportunities, challenges and innovationRisk and protective factors for intuitive and rational judgment of cybersecurity risks in a large sample of K-12 students and teachersLong-term exposure to ambient air pollution is associated with coronary artery calcification among asymptomatic adultsADAM17 Boosts Cholesterol Efflux and Downstream Effects of High-Density Lipoprotein on Inflammatory Pathways in MacrophagesRapid Decrease in HDL-C in the Puberty Period of Boys Associated with an Elevation of Blood Pressure and Dyslipidemia in Korean Teenagers: An Explanation of Why and When Men Have Lower HDL-C Levels Than WomenCeramide Scores Predict Cardiovascular Risk in the CommunityIntegrating lipidomics and genomics: emerging tools to understand cardiovascular diseasesRelationship between lipoproteins, thrombosis, and atrial fibrillationImpact of Blood Pressure Visit‐to‐Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J‐RHYTHM RegistryHow ApoB Measurements Could Improve Prevention of Cardiovascular DiseaseHDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C LevelsPravastatin‐induced changes in expression of long non‐coding and coding RNAs in endothelial cellsGut microbiota and cardiovascular disease: opportunities and challengesObesity-Related Changes in High-Density Lipoprotein Metabolism and FunctionLipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application ProspectsIcosapent ethyl: drug profile and evidence of reduced residual car
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kannel, W. B., Dawber, T. R., FRIEDMAN, G. A. R. Y. D., GLENNON, W. E., & MCNAMARA, P. M. (1964). Risk Factors in Coronary Heart Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-61-5-888
Vancouver
Kannel WB, Dawber TR, FRIEDMAN GARYD, GLENNON WE, MCNAMARA PM. Risk Factors in Coronary Heart Disease. Annals of Internal Medicine. 1964. doi:10.7326/0003-4819-61-5-888. PMID: 14233810.
BibTeX
@article{kannel1964-14233810,
author = {Kannel, William Bernard and Dawber, Thomas R. and FRIEDMAN, GARY D. and GLENNON, WILLIAM E. and MCNAMARA, PATRICIA M.},
title = {{Risk Factors in Coronary Heart Disease}},
journal = {Annals of Internal Medicine},
year = {1964},
doi = {10.7326/0003-4819-61-5-888},
pmid = {14233810},
url = {https://doi.org/10.7326/0003-4819-61-5-888}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The factors associated with excess risk that have been identified are: serum cholesterol level, blood pressure, cigarette smoking, vital capacity,...References1.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Evidence strengthHigh
How this study scored 53/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 31 of the 58 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of Internal Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1964 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 14233810) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 31 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 31 of the 58 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “deaths”
109 studies in the library carry the topic tag “deaths”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 109 tagged studies.